First FDA-Approved Gene Therapy for Genetic Hearing Loss

OTARMENI (lunsotogene parvec-cwha) is an adeno-associated virus vector-based gene therapy given as a single intracochlear infusion (into the inner ear) after thawing. On the US Package Insert it is indicated for pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL) associated with molecularly confirmed biallelic variants in the OTOF gene, preserved outer hair cell function, and no prior cochlear implant in the same ear.

This indication is approved under accelerated approval based on improvement of hearing sensitivity by average pure tone audiometry (PTA) at Week 24. Continued approval may depend on confirmatory clinical benefit.

Limitation of use: OTARMENI is not recommended when preoperative imaging shows that access to the inner ear is not feasible — including abnormal mastoid pneumatization or clinically significant middle-ear / inner-ear anatomic variations.

Distinct path — not this label: A cochlear implant is a different treatment path under its own device rules. Other hearing-loss causes (non-OTOF genetic forms, acquired SNHL, conductive loss) are not this labelled population. Today’s approved US gene-therapy pathway for this OTOF population is Regeneron OTARMENI STN 125874.

The FDA approved BLA 125874/0 on 23 April 2026 under accelerated approval (Commissioner’s National Priority Voucher program). Approval letter addressed to Boning Zhao, PharmD, Regeneron Pharmaceuticals, Inc., Tarrytown, NY. Manufacturer / U.S. License Number 1760. Letter cites associated National Clinical Trial number NCT05788536. Orphan Drug, Rare Pediatric Disease, Fast Track, and Regenerative Medicine Advanced Therapy designations noted on the FDA press announcement. Dual AAV vector–based gene therapy delivering a functional OTOF (otoferlin) coding sequence to inner hair cells.

Where this is taking place

Approved prescription route today: United States — FDA-labelled OTARMENI for the OTOF population above, administered by a surgeon experienced in intracochlear surgery and trained in the OTARMENI procedure, using the cross-labelled Administration Kit. This is an otology / neurotology / pediatric ENT + genetics / audiology conversation with molecular confirmation, imaging, vaccine and corticosteroid planning, and post-procedure monitoring — not a retail pharmacy pickup and not a DIY import.

Outside the United States: At the time of writing, no confirmed Health Canada Notice of Compliance, European Commission marketing authorisation, MHRA licence, TGA ARTG listing, Swissmedic authorisation, or PMDA/MHLW licence for OTARMENI / lunsotogene parvec. Do not import on your own.

Pivotal / ongoing study — NCT05788536 (Study DB-OTO-001; CHORD) — Phase 1/2, open-label, multicenter. Lead sponsor: Regeneron Pharmaceuticals. CT.gov status at the time of writing: recruiting. Estimated enrolment 36. Actual start 27 Jun 2023; estimated primary completion 26 Feb 2029; estimated study completion 25 Feb 2032. Study Director on the record: Clinical Trial Management, Regeneron Pharmaceuticals. Central contact on CT.gov: Clinical Trials Administrator, phone 844-734-6643, email clinicaltrials@regeneron.com. Countries with listed sites include the United States, United Kingdom, Germany, Spain, and Japan. Expanded access: CT.gov reports expanded access: none listed on the record retrieved for this article. The USPI efficacy table uses this ongoing study. Because the record is still recruiting, some people may still be offered trial enrolment at open sites. That is a separate path from labelled commercial US use after approval. Ask the clinician which route they mean.

The practical prescription route in the US is a trained OTARMENI surgical centre working with genetics and audiology to confirm OTOF variants, document outer-hair-cell function, exclude prior implant in the treated ear, complete imaging and vaccine/steroid prep, and schedule the labelled infusion — not treating “recruiting” on CT.gov as proof that every centre is open, and not treating a company free-product statement as a free hospital stay.

Approval matrix

Access by country

• United States: Ask an otology / neurotology / cochlear-implant–experienced surgical team working with genetics and audiology about FDA-labelled OTARMENI. Labelled 23 April 2026 (accelerated) for the OTOF population above. Recommended dose: 7.2×10¹² vg in 0.24 mL per ear, single intracochlear infusion; bilateral in one session when applicable. Confirm biallelic likely pathogenic / pathogenic OTOF variants before dosing. Systemic oral corticosteroids (prednisone-equivalent 1 mg/kg/day, max 60 mg/day) day of infusion × 2 weeks, then taper over 2 weeks. Age-appropriate vaccines ≥1 month before first steroid dose and ≥1 month after last steroid dose; meningitis-pathogen vaccination before surgery as directed. Vial NDC 61755-062-00 (carton 61755-062-01; sealed bag 61755-062-99); Administration Kit NDC 61755-062-11. Store vial frozen −80 °C. Company materials (Regeneron April 2026 announcement) state Regeneron will provide OTARMENI at no cost to clinically eligible individuals in the US via OnPath with OTARMENI patient support 1-866-500-GENE (1-866-500-4363) — and note that administration / hospital costs may still apply outside Regeneron’s control. No list price or copay dollars in this article. Suspected adverse reactions: Regeneron 1-866-500-GENE or FDA MedWatch 1-800-FDA-1088. This is US labelled supply through trained centres, not a DIY import.

• Canada: OTARMENI authorisation not confirmed. Ask the Canadian ENT / genetics clinic what legal paths exist in Canada when a Canadian OTARMENI label does not yet exist.

• European Union / United Kingdom / Australia / Japan / other countries: Regulator authorisation not confirmed on the sources checked. Open or recruiting trial sites are not a foreign marketing authorisation.

• If your regulator has not authorised it: do not import on your own. Ask the local clinician about documented special-access / named-patient rules, referral to a centre in a labelled country, trial enrolment where legally open, or waiting — without treating a US vial as a foreign pack.

Who is eligible (from the US label)

This is an OTOF genetic hearing-loss conversation on the Package Insert — one-time surgical gene therapy — not a cochlear-implant label and not non-OTOF deafness.

United States (Package Insert, revised / issued April 2026):

• Indication: Pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL) associated with molecularly confirmed biallelic OTOF variants, preserved outer hair cell function, and no prior cochlear implant in the same ear.
• Accelerated approval: Based on Week-24 average PTA improvement; confirmatory trial required.
• Limitation: Not recommended when imaging shows inner-ear access is not feasible.
• Before dosing: Confirm biallelic likely pathogenic / pathogenic OTOF variants; trained surgeon; vaccine and corticosteroid prophylaxis as in §2.1; antibiotics before incision.
• Recommended dosage: 7.2×10¹² vg in 0.24 mL per ear; single-dose intracochlear infusion; bilateral same session if applicable.
• Contraindications: None (PI §4).
• Warning: Procedure-related risks (monitor) — may include vertigo, tinnitus, CSF leak, facial paresis, taste change, meningitis, wound infection, mastoiditis, numbness, fluid collection, labyrinthitis (see PI §5.1 / §17).
• Most common adverse reactions (≥5%): otitis media, vomiting, nausea, dizziness, procedural pain, gait disturbance, nystagmus.
• Pediatrics: Safety/effectiveness supported in trial ages 10 months to 16 years on the PI; labelled population includes pediatric and adult patients meeting criteria.
• Geriatrics: Adequate numbers ≥65 not established on sources used here — discuss with clinician.
• Pregnancy / lactation: Discuss with clinician; limited human data on PI.
• Vector shedding: Temporary shedding via body waste — hand hygiene and sealed disposal precautions for 2 weeks after infusion (PI §17).

Not labelled on the sources checked for this article:

• Ears with a prior cochlear implant in the same ear.
• Patients without molecularly confirmed biallelic OTOF variants or without preserved outer hair cell function.
• Canadian, EU, UK, Japanese, Australian, or Swiss OTARMENI marketing authorisations (not confirmed here).
• Treating NCT05788536 recruitment as automatic commercial enrolment everywhere.

What the pivotal study showed (Package Insert)

Use the Package Insert for a prescription / surgical conversation. Journals and company decks are supportive reading.

Study DB-OTO-001 — NCT05788536 (CHORD):

• Ongoing, multi-center, single-arm; pediatric patients with molecularly confirmed OTOF-associated profound SNHL, OHC activity by otoacoustic emissions, cochlear-implant candidates; same-ear CI excluded.
• 24 treated (10 unilateral, 14 bilateral) at 7.2×10¹² vg / 0.24 mL per ear. Median age 2 years (range 10 months–16 years).
• 20 completed Week-24 efficacy assessments (one missing Week-24 imputed as non-responder for the primary).

PI Table 2 — Week 24 efficacy (N=20):

Also at Week 24: 9/20 (45%) reached average PTA ≤45 dB HL; 3/20 (15%) reached ≤25 dB HL. Among 12 evaluated at Week 48: prior responders maintained response; 10/12 (83%) ≤70 dB; 5/12 (42%) ≤25 dB. One patient received a cochlear implant as rescue ~8 months after OTARMENI for treatment failure.

The CT.gov status was recruiting at the time of writing. The study supports the accelerated label and may still enrol at open sites. That is not the same as “walk into any hospital for labelled commercial OTARMENI.” Confirmatory analyses are required under accelerated approval. The approval letter PMR covers outcomes through ~104 weeks in ≥30 treated pediatric patients plus newly treated patients ≥16 years, vs comparable untreated patients.

How it is taken (US label)

Research team (from primary sources only)

• Applicant / manufacturer: Regeneron Pharmaceuticals, Inc., Tarrytown, NY — U.S. License 1760.
• Approval letter attention: Boning Zhao, PharmD (Regeneron).
• Pivotal study sponsor: Regeneron Pharmaceuticals (NCT05788536).
• Study Director (CT.gov): Clinical Trial Management, Regeneron Pharmaceuticals.
• CT.gov central contact: Clinical Trials Administrator — 844-734-6643 / clinicaltrials@regeneron.com.
• Patient support (company): OnPath with OTARMENI — 1-866-500-GENE.
• Names and phones below are limited to what appears on the Package Insert, approval letter, and ClinicalTrials.gov.

Primary sources

1. FDA Package Insert — OTARMENI (lunsotogene parvec-cwha), Issue Date April 2026 — https://www.fda.gov/media/192098/download
2. FDA Accelerated BLA Approval Letter, STN BL 125874/0, 23 April 2026 — https://www.fda.gov/media/192111/download
3. FDA press announcement — First gene therapy for genetic hearing loss (23 April 2026) — https://www.fda.gov/news-events/press-announcements/fda-approves-first-ever-gene-therapy-treatment-genetic-hearing-loss-under-national-priority-voucher
4. FDA OTARMENI product page — https://www.fda.gov/vaccines-blood-biologics/otarmeni
5. ClinicalTrials.gov NCT05788536 (DB-OTO-001 / CHORD)
6. Regeneron company announcement (access / OnPath language) — investor.regeneron.com node 32021 (company statement; not the label)